文献速递前列腺癌

PSA密度联合PI-RADS™对前列腺癌预测准确性的价值

The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction.
PubMed 文献 · J Urol · 2017-03-31

研究纳入1040例疑似前列腺癌男性,先行多参数磁共振成像,再行经会阴系统穿刺及磁共振-经直肠超声融合引导穿刺。按PSA密度分组后计算PI-RADS Likert评分<3的阴性预测值,结果显示PSA密度联合多参数磁共振成像可提高排除显著性前列腺癌的阴性预测值。

要点

  • PSA密度≤0.15 ng/ml/ml时,磁共振阴性男性排除显著性前列腺癌的阴性预测值由79%升至89%。
  • 重复穿刺人群中,显著性前列腺癌阴性预测值由83%升至93%。
  • PSA密度联合多参数磁共振成像后,约20%不必要的穿刺可被安全避免。

核心结论

  • PSA密度联合多参数磁共振成像提高了PI-RADS评分的阴性预测值,约20%不必要的穿刺可被安全避免。

研究设计与样本

  • 研究纳入1040例连续疑似前列腺癌男性,先行多参数磁共振成像,再行经会阴系统穿刺及磁共振-经直肠超声融合引导穿刺。
  • 采用逻辑回归分析检验不同临床因素对显著性前列腺癌的预测价值并构建列线图。
  • 按PSA密度分为3组:第1组小于0.07、第2组0.07至0.15、第3组大于0.15 ng/ml/ml。

主要发现

  • 共451例诊断为显著性前列腺癌,其中187例Gleason评分≥4+3。
  • 列线图预测显著性前列腺癌的AUC高于PI-RADS单独预测(0.79 vs 0.75,p<0.001)。
  • 磁共振阴性男性中,PSA密度≤0.15 ng/ml/ml时显著性前列腺癌阴性预测值由79%升至89%。
  • 重复穿刺人群中,显著性前列腺癌阴性预测值由83%升至93%。
  • 整个队列中,高级别前列腺癌阴性预测值由92%升至98%。

关键数值与推荐

  • 显著性前列腺癌定义为Gleason评分≥3+4。
  • 高级别前列腺癌定义为Gleason评分≥4+3。
  • PSA密度分组阈值为小于0.07、0.07至0.15、大于0.15 ng/ml/ml。

临床怎么用

  • 原文结论认为,使用PSA密度联合多参数磁共振成像提高了PI-RADS评分的阴性预测值。
  • 原文结论认为,通过提高排除显著性前列腺癌的概率,约20%不必要的穿刺可被安全避免。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Multiparametric magnetic resonance imaging has an emerging role in prostate cancer diagnostics. In addition, clinical information is a reliable predictor of significant prostate cancer. We analyzed whether the negative predictive value of multiparametric magnetic resonance imaging to rule out significant prostate cancer could be improved using clinical factors, especially prostate specific antigen density. MATERIALS AND METHODS: A total of 1,040 consecutive men with suspicion of prostate cancer underwent multiparametric magnetic resonance imaging first, followed by transperineal systematic and magnetic resonance imaging-transrectal ultrasound fusion guided biopsy. Logistic regression analyses were performed to test different clinical factors as predictors of significant prostate cancer and build nomograms. To simplify these nomograms for clinical use patients were stratified into 3 prostate specific antigen density groups, including group 1-less than 0.07, group 2-0.07 to 0.15 and group 3-greater than 0.15 ng/ml/ml. After stratification we calculated the negative predictive value of a PI-RADS (Prostate Imaging Reporting and Data System) Likert score of less than 3. Significant prostate cancer was defined as a Gleason score of 3 + 4 or greater. High grade prostate cancer was defined as a Gleason score of 4 + 3 or greater. RESULTS: Overall 451 men were diagnosed with significant prostate cancer, including 187 with a Gleason score of 4 + 3 or greater. On ROC curve analyses the predictive power of the developed nomogram for significant prostate cancer showed a higher AUC than that of PI-RADS alone (0.79 vs 0.75, p <0.001). The negative predictive value of harboring significant prostate cancer increased in men with unsuspicious magnetic resonance imaging from 79% up to 89% when prostate specific antigen density was 0.15 ng/ml/ml or less. In the repeat biopsy setting the negative predictive value of significant prostate cancer increased from 83% to 93%. The negative predictive value to harbor high grade prostate cancer increased from 92% up to 98% in the entire cohort. CONCLUSIONS: Using prostate specific antigen density combined with multiparametric magnetic resonance imaging improved the negative predictive value of PI-RADS scoring. By increasing the probability of ruling out significant prostate cancer approximately 20% of unnecessary biopsies could be avoided safely.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Distler FA, Radtke JP, Bonekamp D, et al. The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction. J Urol. 2017. PMID: 28373135. doi:10.1016/j.juro.2017.03.130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。